Table 4.
Factors associated with receipt of any bone-modifying agent within 180 days of diagnosisa
| Effect | Primary cohort | EFR cohort | LFR cohort |
|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Location | |||
| Hospital outpatient location | [Referent] | [Referent] | [Referent] |
| Physician office location | 1.33 (1.06 to 1.69) | 1.34 (1.04 to 1.73) | 1.21 (0.93 to 1.58) |
| Year of diagnosis | |||
| Before 2010 | [Referent] | [Referent] | [Referent] |
| 2010-2011 | 1.24 (0.91 to 1.70) | 1.10 (0.75 to 1.59) | 1.12 (0.77 to 1.63) |
| 2012 or later | 1.67 (1.31 to 2.13) | 1.23 (0.91 to 1.65) | 1.64 (1.24 to 2.17) |
| Age, y | |||
| <80 | [Referent] | [Referent] | [Referent] |
| ≥80 | 1.04 (0.81 to 1.32) | 1.17 (0.92 to 1.48) | 1.24 (0.95 to 1.63) |
| Race | |||
| Black | 0.90 (0.64 to 1.27) | 0.71 (0.46 to 1.08) | 0.98 (0.66 to 1.44) |
| White | [Referent] | [Referent] | [Referent] |
| Other | 1.04 (0.75 to 1.44) | 1.24 (0.85 to 1.80) | 1.01 (0.70 to 1.48) |
| No. of comorbid conditions | |||
| None | [Referent] | [Referent] | [Referent] |
| 1 | 1.24 (0.95 to 1.60) | 1.05 (0.79 to 1.39) | 1.27 (0.94 to 1.71) |
| ≥2 | 1.01 (0.75 to 1.38) | 1.12 (0.83 to 1.52) | 1.12 (0.79 to 1.58) |
| History of renal failure (vs no history of renal failure) | 1.07 (0.81 to 1.40) | 0.85 (0.64 to 1.13) | 1.07 (0.78 to 1.46) |
| Physician specialty | |||
| Urologist only | [Referent] | [Referent] | [Referent] |
| Oncologist involved | 8.23 (6.41 to 10.57) | 5.53 (4.26 to 7.19) | 7.17 (5.37 to 9.59) |
| Likelihood of dependence in ADLsb | 0.83 (0.36 to 1.93) | 0.64 (0.35 to 1.14) | 0.66 (0.25 to 1.79) |
| Zip code median income | |||
| <$50 000 | [Referent] | [Referent] | [Referent] |
| $50 000-$54 999 | 1.26 (0.88 to 1.79) | 1.18 (0.80 to 1.76) | 1.30 (0.86 to 1.95) |
| $55 000-$59 999 | 0.97 (0.66 to 1.43) | 0.85 (0.55 to 1.31) | 0.90 (0.57 to 1.44) |
| $60 000-$69 999 | 1.12 (0.82 to 1.54) | 1.07 (0.75 to 1.51) | 1.22 (0.85 to 1.75) |
| ≥$70 000 | 1.00 (0.78 to 1.28) | 0.99 (0.76 to 1.30) | 1.00 (0.75 to 1.33) |
a
Logistic regression models were fit separately within each cohort. The EFR cohort comprised patients with a diagnosis of osteoporosis, osteopenia, or bone fracture before PCa diagnosis. The LFR cohort comprised the subset of the primary cohort that had no claims for osteoporosis, osteopenia, any SRE-defining event, or DEXA during the outcome period. ADL = activity of daily living; CI = confidence interval; DEXA = dual-energy x-ray absorptiometry; EFR = elevated fracture risk; LFR = lowest fracture risk; OR = odds ratio; PCa = prostate cancer; SRE = skeletal-related event.
b
Faurot algorithm (28).